News & Analysis on Clinical Trial Services & Contract Research And Development
A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways of improving solubility if the product is to succeed. This also has to be done as quickly and efficiently as possible, with speed of the essence in every drug development program.
This playbook looks at why insolubility is an issue, and the properties that affect solubility.
Paid for and in partnership with Lonza Small Molecules
Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How can they accelerate timelines and reduce costs?
Paid for and in partnership with Lonza Small Molecules
Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug synthesis, speeding up drug substance IND.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug development projects meet tight timelines and budget objectives.
For more product information visit Lonza Small Molecules.